Technologies
Converging science, technologies and data
The interest of precision medicine is no longer in question, but its impact is still limited by the extraordinary heterogeneity of cancers. To overcome this limitation, scientists now have investigative tools of unparalleled precision, scope and speed: very high throughput multiplex analyses, super-resolution imaging, mathematical models of diseases, virtual patient populations, avatars, organoids, genetic engineering, immuno-technologies, etc. All of these technologies will be available in the future oncology district (around the cluster's flagship building, called Oncology Prospective Center) and in the PSCC's satellite sites (some of them as early as 2023).
Discover the PSCC Scientific Offer
Single-cell and Spatial transcriptomic
Organoid platform
Cell Therapy Platform
Clinical trial platform
Surgical platforms
Preclinical Platform in Liver Cancer
Medical Devices platforms
Precision oncology
By specifically addressing the molecular abnormalities that cause disease, targeted therapies have revolutionized the treatment of certain cancers. To adapt these drugs to the real nature of the tumor (a single tumor actually harbors several populations of cancer cells and only some of them carry the molecular abnormality that makes them sensitive to the treatment), the PSCC is opening up access to the best of medical genomics and to very high-resolution single-cell analysis tools.
Single-cell multi-omicsOperator (Phase I): Gustave Roussy Institute
Cancer profiling
Operator: SeqOIA
Cell therapies
Operator: Curie Institute, AP-HP (Meary Center)
Target-antibody duo screening
Operator: MI-mAbs
Immuno-oncology
By restoring the immune system's ability to fight cancer cells, immunotherapy has changed the prognosis of patients with cancers considered incurable (metastatic melanoma, advanced lung cancer, acute lymphoblastic leukemia, etc). Today, the objective is to extend the benefits of this approach to more cancers and patients and to predict and overcome resistance to these treatments (on average only 25% of patients respond to the first available immunotherapies). The platform covers two priority issues: the development of personalized cellular therapies (including CAR-T cells) and the identification of new target-antibody duos and the exploration of the immune response of patients (to pave the way for new immunotherapies).
Predictive models
Preclinical models contribute decisively to advances in oncology but given the low success rate of clinical trials of new drug candidates, their predictivity remains relative. With the Gustave Roussy Institute and the AP-HP, the PSCC is opening up access to ex-vivo models (living cells or tissues from patients maintained in the laboratory) that are closer to the reality of the disease.
Human avatars
Operator: Gustave Roussy Institute
Living pathological tissues and organs
Operators: AP-HM (immune-profiling platform of the Timone hospital) and AP-HP (hepatobiliary center of the Paul-Brousse hospital)
Consulting
Operator: AP-HP (Hôtel Dieu hospital)
Preclinical and clinical trials in oncology
Operator: Groupe Hospitalier Paris Saint-Joseph (BME Lab)
Augmented surgery
Operator: AP-HP (the operating theater of the future, BOPA, Paul Brousse hospital)
Medtech accelerator
Medical technologies and devices play an increasingly important role in oncology (intelligent microsystems, surgical robots, digital applications, etc), but innovators face two major challenges: meeting European regulatory requirements and demonstrating the clinical benefits of their new approaches. To meet these challenges, the PSCC and its partner hospitals have developed a three-part offer.